An observational study in COPD and COPD Exacerbation, sponsored by Respira Labs, Inc. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.
Sponsored by Respira Labs, Inc · Observational
This is a pilot observational study during which the investigators will conduct a longitudinal assessment of air trapping (with up to 2 visits) in 40 patients with COPD and variable degrees of air trapping and 20 healthy controls using ARIA. The investigators will characterize the clinical phenotype of the subjects by administering health and symptom-based questionnaires and obtaining lung function testing at rest and during exertion, and will then correlate and validate the ARIA-based indices with those of the more traditional physiologic measures of static and dynamic air trapping.
Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of hospitalization in the United States. Exacerbations, a worsening or "flare up" of symptoms cause most COPD hospitalizations. Early detection of lung function deterioration would facilitate early intervention and help prevent hospitalizations, since most exacerbations can be treated with changes of inhalers and/or oral medications. Air trapping, defined as an abnormal increase in the volume of air remaining in the lungs after exhalation, is a common finding in all forms of COPD. Air trapping has been shown to increase during exacerbations and decrease when exacerbations resolve. Moreover, increasing recent evidence indicates that air trapping is an earlier harbinger of deteriorating lung function than spirometric changes. Recent research shows that lung air trapping can be measured by low-frequency ultrasound (1-40 kHz). Thus, acoustic monitoring of air trapping could provide clinicians with a non-invasive tool to when medical intervention is needed to avoid unnecessary ER visits and hospitalizations. The investigators have developed a low-cost, non-invasive, acoustic-based wearable device, Sylvee that is capable of continuous monitoring of lung resonance. The device has machine-learning algorithms that can detect minor changes in lung resonance, which our preliminary results suggest corresponds to changes in air trapping. The overall objective of this pilot project is to validate Sylvee's algorithms in a cohort of 60 patients with COPD and variable degree of air trapping. Ultimately, Sylvee will allow physicians to remotely monitor their patients' lung function and adjust their medications to reduce healthcare costs and improve patients' quality of life.
4,131 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 697 are open to participants now.
This study's enrollment of 8 is below the median of 180 across 1,066 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →This is the only study on the registry with Respira Labs, Inc as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Outpatients People who have a condition but who are not being seen as patients Students Staff of UCSF or affiliated institutions
Exclusion Criteria:
20 COPD patients with lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC \[FRC/TLC\])
Device: Sylvee
20 COPD patients without lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC \[FRC/TLC\])
Device: Sylvee
Non COPD patients and non-smokers
Device: Sylvee
The investigators have developed a small sensor that has the same characteristics as a combined hearing aid used for Tinnitus. It has a noise generator intended to transmit white noise (2 - 20 KHz) and a microphone similar to those used in hearing aids to provide sound amplification. Our sensor is substantially equivalent to legally FDA approved marketed devices that can be used for several hours per day. Although it will introduce new indications for use (lung resonance capture), it has the same technological characteristics and will not introduce new hazards or safety risks. Several sound-based devices are already in use for clearing mucus from the lungs by generating and delivering low frequency sound that vibrates the airways and lung secretions, causing them to thin and become expelled. The devices are placed on the patient's chest for up to 3-4 hours in COPD, cystic fibrosis (CF) and other lung diseases.
Change and variability fo acoustic resonance
The change and variability of acoustic resonance features before, during, and after all pulmonary tests, including those where dynamic hyperinflation will be tested: metronome-paced IC, 6-minute walk test and cardio-pulmonary exercise \[every session\]. Acoustic features will be extracted from the measurements with an active acoustic sensor worn on the chest, establishing a baseline before and after all tests. Acoustic resonance changes and their rate of change will be recorded.
Time frame: 4 hours
Correlation between acoustic resonance measurements with clinical testing
The correlation between acoustic resonance measurements and other measurements from pulmonary function tests and wearable devices (respiratory rate, heart rate and oxygen saturation with 80% accuracy rate) before, during (every minute) and after all tests \[every session\]. Acoustic features will be extracted from the measurements with active acoustic sensors worn on the chest. Other measurements will be measured using medical graded devices such as pulse-oximeters and wearables.
Time frame: 2 hours
Correlation between acoustic resonance and symptoms
The correlation between acoustic resonance measurements and patient symptoms and vitals before, during and after all pulmonary function tests, including those where dynamic hyperinflation will be tested: metronome-paced IC, 6-minute walk test and cardio-pulmonary exercise \[every session\]. Acoustic features will be extracted from the measurements with an active acoustic sensor worn on the chest. Patient symptoms and vitals will be collected before and after all tests.
Time frame: 1 hour
Data quality and user experience with medical-grade adhesive
The correlation between medical-grade adhesive options, session length, data quality and patient experience with sensor attachment and detachment procedures. For example: Medical-grade adhesive options will be presented to users at different sessions. Ease of setup, attachment, detachment and data quality will be recorded on a questionnaire for further correlation. A questionnaire with scales from easy-to-hard will be prepared to allow for quantification of different options. The correlation between companion app screens and flows: ease of performing tasks, reading measurements and free-form feedback. Pre-selected alternative application screens, flows and options will be shown to the user in the mobile app and their feedback recorded (free form notes) for User Experience iteration.
Time frame: 30 minutes
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive→